1GLP-1 GLP-1 GLP-1 Pharmaceutical composition for treating muscle atrophy comprising glucagon like-peptide-1 GLP-1 derived peptide or GLP-1 degradation inhibitor
The present invention relates to: a pharmaceutical composition for preventing or treating muscle atrophy or sarcopenia comprising a glucagon-like peptide-1 (GLP-1), a GLP-1 derived peptide, or a GLP-1 decomposition inhibitor; and a method for treating muscle atrophy or sarcopenia by using the pharma...
Saved in:
Main Authors | , , , |
---|---|
Format | Patent |
Language | English Korean |
Published |
01.11.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention relates to: a pharmaceutical composition for preventing or treating muscle atrophy or sarcopenia comprising a glucagon-like peptide-1 (GLP-1), a GLP-1 derived peptide, or a GLP-1 decomposition inhibitor; and a method for treating muscle atrophy or sarcopenia by using the pharmaceutical composition. When the pharmaceutical composition provided by the present invention is administered to a subject having sarcopenia or muscle atrophy, a body weight, a weight of skeletal muscle, a grip power, and expression levels of genes involved in muscle formation reduced due to sarcopenia or muscle atrophy can be restored to a normal state. Therefore, the composition can be widely used for developing effective therapeutic agents for sarcopenia or muscle atrophy.
본 발명은 글루카곤 유사 펩타이드-1(GLP-1), GLP-1 유래 펩타이드, 또는 GLP-1 분해 억제제를 포함하는 근위축증 또는 근감소증 예방 또는 치료용 약학 조성물 및 상기 약학 조성물을 사용하여 근위축증 또는 근감소증을 치료하는 방법에 관한 것이다. 본 발명에서 제공하는 약학 조성물을 근감소증 또는 근위축증이 발병된 개체에 투여하면, 근감소증 또는 근위축증으로 인하여 감소된 체중, 골격근의 중량, 악력 및 근육 생성에 관여하는 유전자의 발현수준을 정상상태로 회복시킬 수 있으므로, 효과적인 근감소증 또는 근위축증의 치료제 개발에 널리 활용될 수 있을 것이다. |
---|---|
Bibliography: | Application Number: KR20190133776 |